Mean absolute change from baseline are mmol/L for all parameters except Apo B, which is in g/L) † a For triglycerides, median absolute change from baseline b Baseline on no lipid-lowering drug Table 1a Response to VYTORIN in Patients with Primary Hypercholesterolaemia (Meana Percent Change from Untreated Baselineb) Treatment Total-C LDL-C B HDL-C TGa Non-HDL-C Pct† Pct† Pct† Pct† Pct† Pct† (Daily Dose) N [Baseline‡] [Baseline‡] [Baseline‡] [Baseline‡] [Baseline‡] [Baseline‡] Pooled data (All VYTORIN 353 -38 -53 -42 +8 -28 -49 doses)c [6.73] [4.52] [1.60] [1.31] [1.90] [5.42] Pooled data (All simvastatin 349 -26 -38 -29 +8 -15 -34 doses)c [6.70] [4.52] [1.59] [1.28] [1.89] [5.42] Ezetimibe10 mg 92 -14 -20 -15 +7 -13 -19 [6.79] [4.55] [1.58] [1.32] [1.85] [5.46] Placebo 93 +2 +3 +3 +2 -2 +2 [6.66] [4.49] [1.59] [1.30] [1.83] [5.36] VYTORIN by dose
† Mean absolute change from baseline are mmol/L for all parameters except Apo B, which is in g/L) a For triglycerides, median absolute change from baseline b Baseline on no lipid-lowering drug Table 1a Response to VYTORIN in Patients with Primary Hypercholesterolaemia (Meana Percent Change from Untreated Baselineb) Treatment (Daily Dose) N Total-C Pct† [Baseline‡] LDL-C Pct† [Baseline‡] B Pct† [Baseline‡] HDL-C Pct† [Baseline‡] TGa Pct† [Baseline‡] Non-HDL-C Pct† [Baseline‡] Pooled data (All VYTORIN doses)c 353 -38 [6.73] -53 [4.52] -42 [1.60] +8 [1.31] -28 [1.90] -49 [5.42] Pooled data (All simvastatin doses)c 349 -26 [6.70] -38 [4.52] -29 [1.59] +8 [1.28] -15 [1.89] -34 [5.42] Ezetimibe10 mg 92 -14 [6.79] -20 [4.55] -15 [1.58] +7 [1.32] -13 [1.85] -19 [5.46] Placebo 93 +2 [6.66] +3 [4.49] +3 [1.59] +2 [1.30] -2 [1.83] +2 [5.36] VYTORIN by dose
auspar-ezetimibe-130228-simvastatin-pi.docx